“The FDA’s Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouroniumdiethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period.”
© 2022 Trioxbio. All Rights Reserved